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Abstract
The compliance with influenza vaccination is poor among health care workers (HCWs) due to misconceptions about safety
and effectiveness of influenza vaccine. We proposed an educational prospective study to demonstrate to HCWs that
influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months
following influenza vaccination. 398 HCWs were surveyed for adverse events (AE) occurring within 48 h of vaccination. AE
were reported by 30% of the HCWs. No severe AE was observed. A subset of 337 HCWs was followed up during four
months, twice a week, for the detection of respiratory symptoms. RV was diagnosed by direct immunofluorescent assay
(DFA) and real time PCR in symptomatic HCWs. Influenza A was detected in five episodes of respiratory symptoms (5.3%)
and other RV in 26 (27.9%) episodes. The incidence density of influenza and other RV was 4.3 and 10.8 episodes per 100
HCW-month, respectively. The educational nature of the present study may persuade HCWs to develop a more positive
attitude to influenza vaccination.
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Introduction
The compliance with influenza vaccination has been histori-
cally poor among health care workers (HCWs) varying from 2 to
36% around the world [1–4]. A recent review of relevant
predictor studies of self-reported reasons for accepting or
rejecting influenza vaccination showed that the two major
reasons for rejecting are misconceptions or lack of knowledge
about influenza infection; and a lack of convenient access to
vaccine. On the other hand, HCWs compliant to seasonal
vaccination are generally older, believe in vaccine efficacy, take
the vaccine for self-protection, and have been previously
vaccinated [5].
At Hospital das Clinicas, University of Sa˜o Paulo School of
Medical Sciences, a previous study showed a 34% compliance
with influenza vaccination among HCWs. In the mentioned
study, the main reasons for non-compliance were the
perception of vaccine inefficacy and the fear of adverse
reactions [4].
Respiratory symptoms occurring after vaccination are frequent-
ly misinterpreted as vaccine failure which reinforces the HCW’s
skepticism on vaccine efficacy. To overcome these false beliefs, we
proposed a prospective study in a cohort of HCWs to demonstrate
that influenza vaccine is safe and other respiratory viruses (but not
influenza) are generally the cause of respiratory symptoms in the
months following influenza vaccination.
Materials and Methods
1. Setting
This study was conducted at Hospital das Clinicas, University of
Sa˜o Paulo School of Medical Sciences (HC-FMUSP) from May to
October 2006. The Hospital das Clinicas is a 2,000-bed tertiary
teaching hospital consisting of 5 buildings attached to the
University of Sa˜o Paulo. The main building has approximately
900 beds and contains most of the surgical and clinical wards and
12 intensive care units. Hospital das Clinicas has an estimated
15,000 HCWs, including permanent and casual staff, employees,
students, and volunteers.
2. Influenza vaccination policies
Since 1999, annual influenza vaccination has been offered free
of charge to all HCWs. Vaccination usually takes place at the
hospital’s Immunization Center during working hours, from
Monday to Friday. In 2006, as a strategy to increase compliance
with influenza vaccination, vaccine was offered at places of easy
access during expanded hours, as suggested by 61% of the
interviewed in previous survey [4]. In addition, an educational
campaign was carried out emphasizing the safety and importance
of influenza vaccination. Detailed information about the 2006
educational and vaccination campaign have been published
elsewhere [6]. The HCW vaccination campaign was conducted
from April 24 to May 8, 2006 and during this period 5,912 health
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professionals were vaccinated. The vaccine composition was A/
New Caledonia/20/99 (H1N1) - like virus, A/California/7/2004
- (H3N2) - like virus and B/Malaysia/25/06/2004 - like virus.
3. Study design
During vaccination campaign, HCWs were invited to partici-
pate in the present study which had two steps: 1) evaluation of
vaccine safety and, 2) cohort study to evaluate which respiratory
viruses were more frequently detected in HCWs presenting
respiratory symptoms in the four-month period following vacci-
nation. Sample size was estimated taking into account an expected
frequency of 10% of adverse events in adult population.
Considering an acceptable frequency rate of up to 13%, we
estimated to enroll at least 377 HCWs (EpiInfo version 6).
4. Study population
Three hundred and ninety eight vaccinated HCWs were
surveyed for adverse events occurring within the first 48 h after
influenza vaccination. A subset of 337 HCWs participated in the
follow-up phase of the study. To assure that all hospital sectors
were represented, the cohort was defined during the assessment of
adverse events which was performed by a hospital epidemiologist
nurse, through visits in all hospital floors and sectors. Afterward,
these HCWs were actively surveyed twice a week, at work place,
during four months, to check for the occurrence of respiratory
symptoms and nasal wash sampling which was done in 93 of the
participants. Figure 1 shows the algorithm of the study. A follow-
up time of four months was proposed taking into account the
period when serum antibodies elicited by influenza vaccine are
expected to maintain protective levels.
5. Surveillance of adverse events and respiratory
symptoms
The following adverse events were actively surveyed: fever,
headache, malaise, myalgia, local pain, local edema and allergic
reaction. Other adverse events spontaneously reported were also
registered. During follow-up visits, participants were asked about
the presence of the following symptoms: fever, coryza, blocked
nose, sneeze, cough, watery eyes, headache, myalgia, sore throat,
hoarseness, sibilance, and dyspnea. Allergy was ruled out in those
with sneezing as the only symptom. Influenza like illness (ILI) was
defined by the presence of fever and cough and/or sore throat
according to the CDC definition [7]. In the presence of any of the
above mentioned symptoms, a nasal wash sample was taken
according to Englund et al, kept at 4uC to 8uC and processed at
the virology laboratory within four hours from sampling [8]. Nasal
washes were taken from HCWs who consent with sampling and
whose duration of symptoms did not exceed three days.
6. Respiratory virus diagnosis
Respiratory syncytial virus (RSV), influenza (INF) A and B,
adenovirus (ADV) and parainfluenza virus (PIV) were diagnosed
by direct immunofluorescent assay (DFA) according to the
manufacturer’s instructions (ImagenH DAKO, Cambridgeshire,
UK). Aliquots of NW samples were stored at280uC for later PCR
and real time PCR processing. PCR was used to detect
coronavirus and picornavirus. RT-PCR products for picornavirus
were subsequently sequenced to differentiate rhinovirus from
enteroviruses. Real time PCR (Taqman assay) was used to
diagnose human metapneumovirus (hMPV). To increase the
sensitivity of influenza diagnosis, a real time PCR (Taqman assay),
was added to the diagnostic tools. Similarly, a nested adenovirus
PCR was used along with DFA due to the low sensitivity of the
latter in diagnosing ADV. The PCR protocols used in the present
study have been published elsewhere [9–12]. HCWs were
informed about the results of the DFA up to 48 h after sampling.
7. Ethics Statement and informed consent
The study was approved on 04/12/2006 by local Ethics
Committee with the following statement: ‘‘A Comissa˜o de E´tica para
ana´lise de projetos de Pesquisa - CAPPEsq da Diretoria Clı´nica do Hospital
das Clı´nicas e da Faculdade de Medicina da Universidade de Sa˜o Paulo, em
sessa˜o de 12/04/2006, aprovou o Protocolo de Pesquisa no. 241/06,
intitulado Viroses respirato´rias apo´s vacinac¸a˜o contra influenza em
profissionais de sau´de, apresentado pelo Departamento de Mole´stias Infecciosas
e Parasita´rias, inclusive o Termo de Consentimento Livre e Esclarecido.
Figure 1.
doi:10.1371/journal.pone.0030670.g001
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CAPPesq, 12/04/2006’’. Written informed consent was obtained
from all participants.
8. Statistical analysis
SPSS 15.0 (SPSS Inc., Chicago, IL) was used with the x2 test or
Fisher’s exact test for discrete variables, and Student’s t test or the
Mann-Whitney U test for continuous variables. Tests of
significance were two sided, and p,0.05 was considered to be
statistically significant. Incidence density (ID) of respiratory
symptoms, influenza virus infections and other respiratory virus
infections were calculated by the formula described below. ID
results were expressed per 100 HCW-month [13].
ID event~
No: of HCW with the event
Total no: of HCW x event follow{up time (mean)
Results
The interviews for adverse events occurring within 48 h of
vaccination were made from one to 10 days after vaccination. The
majority of the participants (81.4%) were surveyed within the first
week of vaccination. All hospital sectors were represented (Table 1).
One hundred and twenty of the 398 HCWs (30.2%) reported at
least one adverse event (AE). Table 1 shows the occurrence of
adverse events according to the demographic characteristics of the
vaccinees. Sector of work was the only variable associated with the
presence of adverse events (p = 0.017). The sectors with highest
frequency of adverse events were the Virology Laboratory (87.5%
of the subjects), Burn unit (54.5%), Nephrology (52.4%) and
Pneumology (45.5%). In the remaining sectors, AE were reported
by less than 40% of the subjects. Those surveyed in the first five
days after vaccination were more likely to report such events [95
(79.2%) versus 25 (20.8%); p,0.0001]. Local AE were reported by
18.3% of the participants, systemic AE by 71.6%, and 10% of the
participants reported both local and systemic AEs. Headache,
myalgia and malaise were more frequently reported (50%, 45.8%
and 45%, respectively). Local pain and local edema was reported
by 17.5% and 5% of the HCWs. No severe adverse event was
observed.
During the 4-month period following influenza vaccination,
respiratory symptoms were evaluated in 337 HCWs. A total of
4,182 follow-up visits were performed (median 12 per HCW,
ranging from one to 25 visits).
One hundred and twenty-one HCWs (36%) developed 192
episodes of respiratory symptoms. Coryza, cough, sore throat and
myalgia were reported by 36.3%, 25%, 17.4% and 13.7% of the
participants, respectively. Seventy-one of them (58.7%) presented
more than one episode suggestive of upper respiratory infection
(URI). ILI was observed in 17 of the 192 episodes (8.8%). Mean
time to the occurrence of respiratory symptoms was 2.9 (0.7 to 5.2)
months. The incidence density of respiratory symptoms was 12.4
episodes per 100 HCW-month.
Nasal washes were taken in 93 of the 192 episodes of URI. In 61
episodes (66.3%) no respiratory virus was found, even though 82%
had coryza, 53% had cough and 49% had sore throat. The
frequency of ILI was similar among HCWs who agreed with
sampling and those who did not agree (58.8% versus 41.2%,
p = 0.37) (Table 2).
Influenza A virus was detected in 5 of 93 episodes (5.4%),
considering both techniques. DFA diagnosed two cases and real
time PCR detected three additional ones. Respiratory symptoms
in HCWs with influenza are described on table 3. Influenza cases
occurred at a median of 40 days after vaccination, ranging from 34
to 56 days and were considered vaccine failures. Mean time to
influenza diagnosis was 1.24 months. Incidence density of
influenza was 4.3 cases per 100 HCW-month.
Other respiratory viruses were diagnosed in 26 of the 93
episodes (28.3%) of URI. Rhinovirus and coronavirus were the
RV more frequently detected (Table 4). Mean time to the
occurrence of other RV infections was 2.72 months. Incidence
density of other RV was 10.3 cases per 100 HCW-month. Other
RV infections occurred significantly later than influenza cases
during follow-up (p = 0.04).
Discussion
Misconceptions about influenza vaccine, be it about its safety or
its effectiveness, have been identified in all studies included in a
recent review of attitudes and predictors of influenza vaccination
among HCWs, highlighting the importance of education efforts
[5].
Initial symptoms of RV infections are often unspecific such as
fever, malaise, or myalgia. As influenza vaccine is offered when
other RV are circulating (e.g., RSV), vaccinated HCWs
developing symptoms within 48 h of vaccination misinterpret
those signs as vaccine adverse events. In addition, the occurrence
of respiratory symptoms in the months following vaccination is
mistaken as vaccine failure. Other respiratory infections as the
cause of such symptoms are hardly ever considered.
To diminish the arguments of fear of adverse events or
perception of vaccine inefficacy, this prospective study was
conducted to demonstrate to a subset of HCWs from our hospital,
that severe adverse events following influenza vaccination are rare
and the episodes of respiratory symptoms occurring in the first
four months after vaccination are generally caused by other
respiratory viruses and not by influenza virus.
As expected, no severe adverse event was observed in the
present study, and the events more frequently reported, such as
headache, myalgia and malaise could be related to influenza
vaccine itself as well as to other causes, given their unspecificity.
In adults, the adverse event more frequently reported after
intramuscular administration of inactivate vaccines is local pain,
affecting 10% to 64% of the vaccinated [14–16]. In the present
study, 17.5% of the participants reported local pain.
Systemic reactions like fever, malaise and myalgia can also
occur after inactivate vaccines. In the present study, the frequency
of systemic AEs (over 70%) was higher than reported in previous
studies. Recent publications have shown rates of systemic adverse
events ranging from 30% to 59% in HWCs [17,18]. Ideally, the
subjects should have been surveyed within the first four days of
vaccination. As we preferred to apply the questionnaire personally,
rather than by mail or phone calls, only 49.7% of the participants
were interrogated up to the fourth day, due to the great number of
interviews. Thus, the high rate of systemic adverse events observed
in the present series may be either an overestimation by the
subjects or a consequence of the survey method applied. A recent
study evaluating vaccine coverage in Korea has demonstrated that
interview surveys provide more reliable information than tele-
phone surveys, showing lower missing rates and 100% of
agreement with the immunization registry record [18].
Anaphylaxis and neurological reactions are rare [15,19]. The
frequency of adverse events observed in the present study may be
overestimated taking into account the subjectiveness of self-
reported unspecific symptoms.
As HCWs are aware of vaccine adverse events and fear its
consequences, it is comprehensible that these events will be more
Educating HCWs to Comply with Influenza Vaccine
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frequently reported by them than by general population. Another
study conducted in the same hospital demonstrated that HCWs
reported significantly more adverse events (52.9%) than the elderly
(25.3%) [20]. The higher frequency of adverse events reported by
HCWs surveyed in the first five days of vaccination, as compared
with those surveyed after the fifth day, may suggest that people
may be more predisposed to remember any symptom possibly
associated with the vaccine if inquired within the first days of
vaccination. On the other hand, we believe that if the adverse
events were severe or important, they would not be missed if
inquired after 6 to 10 days.
Interestingly, we observed that some sectors showed significant-
ly higher rates of AE than others, supporting the subjectivity of the
information. Also, this data may suggest a mouth to mouth effect
among sector coworkers influencing the self-report of AE. Among
HCWs, the belief that coworkers take influenza vaccine influences
the vaccine uptake. Thus, it is possible that the same occurs
concerning to adverse events.
Continued education of health professionals is essential to
highlight not only the epidemiological importance of the vaccine,
but also its safety and the low risk of severe adverse events.
Our study also demonstrated that the respiratory symptoms
occurring in the months following influenza vaccination were
more frequently caused by other respiratory viruses and generally
do not mean vaccine failures.
One limitation of our study is that in only 93 of the 192 episodes
of respiratory symptoms (48.4%) the subjects agreed with NW
sampling. NW sampling is a simple but uncomfortable procedure
and this fact may explain why some HCWs preferred not to get
tested during working hours. One could argue that influenza cases
Table 1. Demographic characteristics of HCWs surveyed for adverse events (AE).
Variable Category Distribution (%) Number (%) p value
Without AE With AE
Age* (years) 18–35 195 (49.5) 138 (70.8) 57 (29.2) 0.84
36–80 199 (50.5) 139 (69.8) 60 (30.2)
Gender Male 42 (10.6) 30 (71.4) 12 (28.6) 0.81
Female 356 (89.4) 248 (69.7) 108 (30.3)
Sector Emergence room 56 (14.0) 40 (71.4) 16 (28.6) 0.017
General surgery 42 (10.6) 33 (78.6) 09 (21.4)
Internal medicine 34 (8.5) 30 (88.2) 04 (11.8)
Pneumology 22 (5.5) 12 (54.5) 10 (45.5)
Nephrology 21 (5.3) 10 (47.60 11 (52.4)
Neonate unit 19 (4.8) 13 (68.4) 06 (31.6)
Neurology 18 (4.5) 12 (66.7) 06 (33.3)
Hematology/HSCT 17 (4.3) 13 (76.5) 04 (23.5)
Maintenance 17 (4.3) 11 (64.7) 06 (35.3)
Liver transplantation 15 (3.8) 09 (60) 06 (40)
Obstetrics/Gynecology 14 (3.5) 12 (85.7) 02 (14.3)
Infectious diseases 13 (3.3) 11 (84.6) 02 (15.4)
Operating room 12 (3.0) 09 (75) 03 (25)
Burn unit 11 (2.8) 05 (45.5) 06 (54.5)
Renal transplantation 10 (2.5) 06 (60) 04 (40)
Geriatrics 09 (2.3) 06 (66.7) 03 (33.3)
Virology laboratory 08 (2.0) 01 (12.5) 07 (87.5)
Ophthalmology 05 (1.3) 04 (80) 01 (20)
Dermatology 05 (1.3) 05 (100) 0 (0)
Urology 05 (1.3) 04 (80) 01 (20)
Rheumatology 05 (1.3) 03 (60) 02 (40)
Vascular surgery 05 (1.3) 04 (80) 01 (20)
Other 35 (8.8) 25 (71.4) 10 (28.6)
(*) Information not available in 4 subjects. HSCT = hematopoietic stem cell transplantation.
doi:10.1371/journal.pone.0030670.t001
Table 2. Influenza-like illnesses in HCWs according to
acceptance of nasal wash sampling.
Influenza-like illness Agreed with sampling (%) Total
No Yes
No 92 (47.9) 83 (43.2) 175 (91.1)
Yes 07 (3.6) 10 (5.2) 17 (8.9)
Total 99 (51.6) 93 (48.4) 192 (100)
(p= 0.37; Pearson x2 test).
doi:10.1371/journal.pone.0030670.t002
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could be missed among those not tested. However, we believe that
this loss has not affected our results as the frequency of ILI was
similar between those who agreed with sampling and those who
did not (Table 2, p = 0.37).
The incidence density of other respiratory viruses was 2.4 times
greater than incidence density of influenza. Probably, this
difference would be even greater if real time PCR was also
performed to increase the sensitivity of the diagnosis of other
respiratory viruses as well. In addition, more cases of other RV
infections would be diagnosed if a larger number of professionals
were tested, increasing the difference between the incidence
density of influenza and other RV.
Influenza infection is characterized by the abrupt occurrence of
fever, headache, myalgia, and dry cough. During influenza season,
the presence of these symptoms is highly predictive of influenza
infection and summarizes the case definition of influenza-like illness
(ILI), which has been used worldwide for influenza surveillance
purposes. However, the sensitivity and positive predictive value of
such definition can vary greatly depending on the co-circulation of
other respiratory viruses in the community [21]. Indeed, Bellei
et al. have recently reported that 70% of ILI cases in the city of
Sa˜o Paulo were caused by other agents, mainly rhinovirus, which
peaks along with influenza [22]. Similar results have been
previously published by other authors [21].
In our series, influenza cases in vaccinated HCWs were mild
and occurred significantly earlier following vaccination in
comparison to other respiratory viruses. This finding may be
explained by the marked seasonality of influenza in Sa˜o Paulo city
as reported previously [23,24], peaking in early winter and
coinciding with the initial period of the study.
The effectiveness of influenza vaccines is related predomi-
nantly to the age and immune competence of the vaccinee and
the degree of similarity between the viruses in the vaccine and
those in circulation. Vaccine effectiveness in preventing
laboratory-confirmed influenza illness when the vaccine strains
are well matched to circulating strains is 70–90% in
randomized, placebo-controlled trials conducted among chil-
dren and young healthy adults, but is lower among elderly or
immunocompromised persons [25]. In adults $65 years old,
the efficacy of influenza inactivate vaccine varies from 30% to
40% [26].
Trials that measure laboratory-confirmed influenza virus
infections as the outcome are the most persuasive evidence of
vaccine efficacy [25]. In the present study, only five of the 337
vaccinated HCWs (1.5%) acquired influenza.
In accordance with the educational nature of our study, we
considered all cases of influenza as vaccine failures, since
vaccinated health personnel look forward to be protected against
influenza. Molecular characterization of influenza cases was not
performed to check for possible mismatches between circulating
viruses and vaccine strains, which could possibly justify those
failures.
Our study demonstrated that the fear of severe adverse events
seems unjustified as well as the perception of vaccine inefficacy.
URI following influenza vaccination were generally caused by
other respiratory viruses and not by influenza.
In times of pandemic influenza A H1N1 and widespread
vaccination, healthcare and emergency medical services personnel
are among the priority groups recommended to receive the H1N1
influenza vaccine. It is time to overcome definitively the
misconceptions about the vaccine as well as the fear of adverse
events. So far, the vast majority (93%) of adverse events reported
to VAERS after receiving the trivalent 2010–2011 influenza
vaccine, were classified as ‘‘non serious’’, e.g., soreness at the
vaccine injection site [27].
We believe that the educational nature of the present study may
persuade HCWs to develop a more positive attitude to influenza
vaccination.
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Table 3. Time to influenza diagnosis according to vaccination date of HCWs and respective workplaces.
Case Influenza symptoms Vaccine date
Influenza
diagnosis Dt Sector
1 Cough, sneezing, coryza 04/27/06 05/31/06 34 Internal Medicine
2 Fever, sore throat 04/26/06 06/01/06 36 Urology
3 Nasal congestion, cough, myalgia, sibilance 04/27/06 06/06/06 40 Internal Medicine
4 Coryza, headache 04/26/06 06/06/06 41 Trauma ICU
5 Fever, coryza, headache, nasal congestion, myalgia 04/25/06 06/20/06 56 Nephrology
doi:10.1371/journal.pone.0030670.t003
Table 4. Other respiratory viruses diagnosed by DFA and/or
PCR/real time PCR.
Respiratory Virus No. tested positive %
Respiratory syncytial virus 1 3.2%
Adenovirus 2 6.5%
Coronavirus 7 22.5%
Influenza A 5 16.1%
Metapneumovirus 3 9.6%
Rhinovirus 9 29.0%
Adenovirus+Coronavirus 1 3.2%
Metapneumovirus+Rhinovirus 1 3.2%
Rhinovirus+Coronavirus 1 3.2%
Respiratory syncytial virus+Adenovirus 1 3.2%
TOTAL 31 100.0%
doi:10.1371/journal.pone.0030670.t004
Educating HCWs to Comply with Influenza Vaccine
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e30670
References
1. Bishburg E, Shah M, Mathis AS (2008) Influenza vaccination among medical
residents in a teaching hospital. Infect Control Hosp Epidemiol 29: 89–91.
10.1086/524322 [doi].
2. Christini AB, Shutt KA, Byers KE (2007) Influenza vaccination rates and
motivators among healthcare worker groups. Infect Control Hosp Epidemiol 28:
171–177. ICHE2006270 [pii];10.1086/511796 [doi].
3. Smedley J, Poole J, Waclawski E, Stevens A, Harrison J, et al. (2007) Influenza
immunisation: attitudes and beliefs of UK healthcare workers. Occup Environ
Med 64: 223–227. oem.2005.023564 [pii];10.1136/oem.2005.023564 [doi].
4. Takayanagi IJ, Cardoso MR, Costa SF, Araya ME, Machado CM (2007)
Attitudes of health care workers to influenza vaccination: why are they not
vaccinated? Am J Infect Control 35: 56–61. S0196-6553(06)01009-1
[pii];10.1016/j.ajic.2006.06.002 [doi].
5. Hollmeyer HG, Hayden F, Poland G, Buchholz U (2009) Influenza vaccination
of health care workers in hospitals–a review of studies on attitudes and
predictors. Vaccine 27: 3935–3944. S0264-410X(09)00469-1 [pii];10.1016/
j.vaccine.2009.03.056 [doi].
6. Lopes MH, Sartori AM, Mascheretti M, Chaves TS, Andreoli RM, et al. (2008)
Intervention to increase influenza vaccination rates among healthcare workers in
a tertiary teaching hospital in Brazil *. Infect Control Hosp Epidemiol 29:
285–286. 10.1086/528700 [doi].
7. (2010) Update: influenza activity–United States, August 30, 2009–January 9,
2010. MMWR Morb Mortal Wkly Rep 59: 38–43. mm5902a3 [pii].
8. Englund JA, Piedra PA, Jewell A, Patel K, Baxter BB, et al. (1996) Rapid
diagnosis of respiratory syncytial virus infections in immunocompromised adults.
J Clin Microbiol 34: 1649–1653.
9. Arruda E, Hayden FG (1993) Detection of human rhinovirus RNA in nasal
washings by PCR. Mol Cell Probes 7: 373–379. S0890-8508(83)71055-8
[pii];10.1006/mcpr.1993.1055 [doi].
10. Morris DJ, Cooper RJ, Barr T, Bailey AS (1996) Polymerase chain reaction for
rapid diagnosis of respiratory adenovirus infection. J Infect 32: 113–117. S0163-
4453(96)91250-5 [pii].
11. Oliveira R, Machado A, Tateno A, Boas LV, Pannuti C, et al. (2008) Frequency
of human metapneumovirus infection in hematopoietic SCT recipients during 3
consecutive years. Bone Marrow Transplant 42: 265–269. bmt2008153
[pii];10.1038/bmt.2008.153 [doi].
12. van Elden LJ, Nijhuis M, Schipper P, Schuurman R, van Loon AM (2001)
Simultaneous detection of influenza viruses A and B using real-time quantitative
PCR. J Clin Microbiol 39: 196–200. 10.1128/JCM.39.1.196-200.2001 [doi].
13. Rothman KJ, Greenland S (1998) Measures of disease frequency. In:
Rothman KJ, Greenland S, eds. Modern Epidemiology. Philadelphia:
Lippincott Williams & Wilkins. pp 29–46.
14. Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, et al.
(2000) Effectiveness and cost-benefit of influenza vaccination of healthy working
adults: A randomized controlled trial. JAMA 284: 1655–1663. joc01494 [pii].
15. Margolis KL, Poland GA, Nichol KL, MacPherson DS, Meyer JD, et al. (1990)
Frequency of adverse reactions after influenza vaccination. Am J Med 88:
27–30. 0002-9343(90)90123-U [pii].
16. Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, et al. (1995) The
effectiveness of vaccination against influenza in healthy, working adults.
N Engl J Med 333: 889–893.
17. Igari H, Segawa S, Watanabe A, Suzuki A, Watanabe M, et al. (2010)
Immunogenicity of a monovalent pandemic influenza A H1N1 vaccine in
health-care workers of a university hospital in Japan. Microbiol Immunol 54:
618–624. 10.1111/j.1348-0421.2010.00254.x [doi].
18. Park SW, Lee JH, Kim ES, Kwak YG, Moon CS, et al. (2011) Adverse events
associated with the 2009 H1N1 influenza vaccination and the vaccination
coverage rate in health care workers. Am J Infect Control 39: 69–71. S0196-
6553(10)00816-3 [pii];10.1016/j.ajic.2010.08.007 [doi].
19. Donalisio MR, Ramalheira RM, Cordeiro R (2003) [Adverse reactions to
influenza vaccine in the elderly, Campinas District, SP, 2000]. Rev Soc Bras
Med Trop 36: 467–471. S0037-86822003000400006 [pii].
20. Lopes MH, Mascheretti M, Franco MM, Vasconcelos R, Gutierrez EB (2008)
Occurrence of early adverse events after vaccination against influenza at a
Brazilian reference center. Clinics (Sao Paulo) 63: 21–26. S1807-
59322008000100005 [pii].
21. Boivin G, Hardy I, Tellier G, Maziade J (2000) Predicting influenza infections
during epidemics with use of a clinical case definition. Clin Infect Dis 31:
1166–1169. CID000111 [pii];10.1086/317425 [doi].
22. Bellei N, Carraro E, Perosa A, Watanabe A, Arruda E, et al. (2008) Acute
respiratory infection and influenza-like illness viral etiologies in Brazilian adults.
J Med Virol 80: 1824–1827. 10.1002/jmv.21295 [doi].
23. Machado CM, Boas LS, Mendes AV, Santos MF, da Rocha IF, et al. (2003) Low
mortality rates related to respiratory virus infections after bone marrow
transplantation. Bone Marrow Transplant 31: 695–700. 10.1038/sj.bmt.1703900
[doi];1703900 [pii].
24. Machado CM, Boas LS, Mendes AV, da Rocha IF, Sturaro D, et al. (2004) Use of
Oseltamivir to control influenza complications after bone marrow transplantation.
Bone Marrow Transplant 34: 111–114. 10.1038/sj.bmt.1704534 [doi];1704534
[pii].
25. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, et al. (2009) Prevention
and control of seasonal influenza with vaccines: recommendations of the
Advisory Committee on Immunization Practices (ACIP), 2009. MMWR
Recomm Rep 58: 1–52. rr5808a1 [pii].
26. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA (1995) The
efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the
literature. Ann Intern Med 123: 518–527.
27. [Anonymous] (11 A.D.) Summary of 2010–2011 Trivalent Influenza Vaccine
Data from the U.S. Vaccine Adverse Event Reporting System. http://vaers hhs
gov/resources/SeasonalFluSummary_2011April05 pdf.
Educating HCWs to Comply with Influenza Vaccine
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e30670
